- Home
- VIVS vs PPBT Comparison
VIVS vs PPBT Comparison
Compare VIVS & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIVS
- PPBT
- Stock Information
- Founded
- VIVS 2007
- PPBT 2010
- Country
- VIVS United States
- PPBT Israel
- Employees
- VIVS N/A
- PPBT N/A
- Industry
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- VIVS Health Care
- PPBT Health Care
- Exchange
- VIVS Nasdaq
- PPBT Nasdaq
- Market Cap
- VIVS 4.7M
- PPBT 5.5M
- IPO Year
- VIVS N/A
- PPBT N/A
- Fundamental
- Price
- VIVS $3.19
- PPBT $0.58
- Analyst Decision
- VIVS
- PPBT Strong Buy
- Analyst Count
- VIVS 0
- PPBT 1
- Target Price
- VIVS N/A
- PPBT $33.00
- AVG Volume (30 Days)
- VIVS 166.7K
- PPBT 408.1K
- Earning Date
- VIVS 11-07-2025
- PPBT 11-14-2025
- Dividend Yield
- VIVS N/A
- PPBT N/A
- EPS Growth
- VIVS N/A
- PPBT N/A
- EPS
- VIVS N/A
- PPBT N/A
- Revenue
- VIVS $142,000.00
- PPBT N/A
- Revenue This Year
- VIVS $42.38
- PPBT N/A
- Revenue Next Year
- VIVS $15.42
- PPBT N/A
- P/E Ratio
- VIVS N/A
- PPBT N/A
- Revenue Growth
- VIVS 94.52
- PPBT N/A
- 52 Week Low
- VIVS $1.41
- PPBT $0.53
- 52 Week High
- VIVS $21.96
- PPBT $13.95
- Technical
- Relative Strength Index (RSI)
- VIVS 51.15
- PPBT 19.96
- Support Level
- VIVS $2.90
- PPBT $0.57
- Resistance Level
- VIVS $3.48
- PPBT $0.62
- Average True Range (ATR)
- VIVS 0.34
- PPBT 0.03
- MACD
- VIVS -0.09
- PPBT 0.06
- Stochastic Oscillator
- VIVS 20.86
- PPBT 45.09
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.